Preliminary study of Conbercept injected intravitreally for the treatment of wet age-related macular degeneration
AIM:To observe the preliminary efficacy of conbercept injected intravitreally for the treatment of wet age-related macular degeneration(wAMD).<p<METHODS:Seventeen wAMD patients(18 eyes)were selected to receive conbercept injection. All patients were given a single conbercept injection every mo...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Ying Qin [verfasserIn] Shao-Feng Hao [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Guoji Yanke Zazhi - Press of International Journal of Ophthalmology (IJO PRESS), 2017, 17(2017), 8, Seite 1554-1557 |
|---|---|
| Übergeordnetes Werk: |
volume:17 ; year:2017 ; number:8 ; pages:1554-1557 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.3980/j.issn.1672-5123.2017.8.40 |
|---|
| Katalog-ID: |
DOAJ023830581 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ023830581 | ||
| 003 | DE-627 | ||
| 005 | 20230307070921.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3980/j.issn.1672-5123.2017.8.40 |2 doi | |
| 035 | |a (DE-627)DOAJ023830581 | ||
| 035 | |a (DE-599)DOAJa22d9356a8764eb6b70a29c8c846b898 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RE1-994 | |
| 100 | 0 | |a Ying Qin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preliminary study of Conbercept injected intravitreally for the treatment of wet age-related macular degeneration |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a AIM:To observe the preliminary efficacy of conbercept injected intravitreally for the treatment of wet age-related macular degeneration(wAMD).<p<METHODS:Seventeen wAMD patients(18 eyes)were selected to receive conbercept injection. All patients were given a single conbercept injection every month, 3 times. Before and after 1, 2, 3mo of the injection, the best corrected visual acuity(BCVA), intraocular pressure(IOP, measured by Non-contact tonometer), fundus photography, fundus fluorescein angiography(FFA), indocyanine green angiography(ICG), optical coherence tomography(OCT)examination and the complications incidence were compared.<p<RESULTS:Three months after conbercept injection, the BCVA improved in 15 eyes(83%), stable in 3 eyes(17%). Before treatment, the average central macular thickness was 421.72±54.43μm, at 1 and 2 and 3mo after treatment, the average central macular thickness was 337.89±25.88μm, 293.56±26.87μm, 266.89±19.10μm respectively. There were significant differences compared with before and after injection(<i<P</i<<0.05). In the final follow up, FFA and ICG showed that the leakage in macular area disappeared in 15 eyes(83%), still existed in 3 eyes(17%), in those 3 eyes the injection was given for one or two times till the leakage disappeared. Elevated intraocular pressure occurred in 2 cases(26mmHg, 23mmHg), after 1d down to normal. Another patient showed postoperative envy, given left ofloxacin eye drops after 2d,then back to normal. There was no serious ocular adverse reactions. <p<CONCLUSION:Intravitreal injection conbercept for wAMD can significantly improve the visual function, reduce the macular edema and the leakage with higher safety and less complications. However the prolonged efficacy needs further observation. | ||
| 650 | 4 | |a conbercept | |
| 650 | 4 | |a wet age related macular degeneration | |
| 650 | 4 | |a choroidal neovascularization | |
| 653 | 0 | |a Ophthalmology | |
| 700 | 0 | |a Shao-Feng Hao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Guoji Yanke Zazhi |d Press of International Journal of Ophthalmology (IJO PRESS), 2017 |g 17(2017), 8, Seite 1554-1557 |w (DE-627)1680946854 |x 16725123 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2017 |g number:8 |g pages:1554-1557 |
| 856 | 4 | 0 | |u https://doi.org/10.3980/j.issn.1672-5123.2017.8.40 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/a22d9356a8764eb6b70a29c8c846b898 |z kostenfrei |
| 856 | 4 | 0 | |u http://ies.ijo.cn/cn_publish/2017/8/201708040.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1672-5123 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1672-5123 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_2817 | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2017 |e 8 |h 1554-1557 | ||
| author_variant |
y q yq s f h sfh |
|---|---|
| matchkey_str |
article:16725123:2017----::rlmnrsuyfobretnetdnrvtelyoteramnowtg |
| hierarchy_sort_str |
2017 |
| callnumber-subject-code |
RE |
| publishDate |
2017 |
| allfields |
10.3980/j.issn.1672-5123.2017.8.40 doi (DE-627)DOAJ023830581 (DE-599)DOAJa22d9356a8764eb6b70a29c8c846b898 DE-627 ger DE-627 rakwb eng RE1-994 Ying Qin verfasserin aut Preliminary study of Conbercept injected intravitreally for the treatment of wet age-related macular degeneration 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier AIM:To observe the preliminary efficacy of conbercept injected intravitreally for the treatment of wet age-related macular degeneration(wAMD).<p<METHODS:Seventeen wAMD patients(18 eyes)were selected to receive conbercept injection. All patients were given a single conbercept injection every month, 3 times. Before and after 1, 2, 3mo of the injection, the best corrected visual acuity(BCVA), intraocular pressure(IOP, measured by Non-contact tonometer), fundus photography, fundus fluorescein angiography(FFA), indocyanine green angiography(ICG), optical coherence tomography(OCT)examination and the complications incidence were compared.<p<RESULTS:Three months after conbercept injection, the BCVA improved in 15 eyes(83%), stable in 3 eyes(17%). Before treatment, the average central macular thickness was 421.72±54.43μm, at 1 and 2 and 3mo after treatment, the average central macular thickness was 337.89±25.88μm, 293.56±26.87μm, 266.89±19.10μm respectively. There were significant differences compared with before and after injection(<i<P</i<<0.05). In the final follow up, FFA and ICG showed that the leakage in macular area disappeared in 15 eyes(83%), still existed in 3 eyes(17%), in those 3 eyes the injection was given for one or two times till the leakage disappeared. Elevated intraocular pressure occurred in 2 cases(26mmHg, 23mmHg), after 1d down to normal. Another patient showed postoperative envy, given left ofloxacin eye drops after 2d,then back to normal. There was no serious ocular adverse reactions. <p<CONCLUSION:Intravitreal injection conbercept for wAMD can significantly improve the visual function, reduce the macular edema and the leakage with higher safety and less complications. However the prolonged efficacy needs further observation. conbercept wet age related macular degeneration choroidal neovascularization Ophthalmology Shao-Feng Hao verfasserin aut In Guoji Yanke Zazhi Press of International Journal of Ophthalmology (IJO PRESS), 2017 17(2017), 8, Seite 1554-1557 (DE-627)1680946854 16725123 nnns volume:17 year:2017 number:8 pages:1554-1557 https://doi.org/10.3980/j.issn.1672-5123.2017.8.40 kostenfrei https://doaj.org/article/a22d9356a8764eb6b70a29c8c846b898 kostenfrei http://ies.ijo.cn/cn_publish/2017/8/201708040.pdf kostenfrei https://doaj.org/toc/1672-5123 Journal toc kostenfrei https://doaj.org/toc/1672-5123 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_2817 AR 17 2017 8 1554-1557 |
| spelling |
10.3980/j.issn.1672-5123.2017.8.40 doi (DE-627)DOAJ023830581 (DE-599)DOAJa22d9356a8764eb6b70a29c8c846b898 DE-627 ger DE-627 rakwb eng RE1-994 Ying Qin verfasserin aut Preliminary study of Conbercept injected intravitreally for the treatment of wet age-related macular degeneration 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier AIM:To observe the preliminary efficacy of conbercept injected intravitreally for the treatment of wet age-related macular degeneration(wAMD).<p<METHODS:Seventeen wAMD patients(18 eyes)were selected to receive conbercept injection. All patients were given a single conbercept injection every month, 3 times. Before and after 1, 2, 3mo of the injection, the best corrected visual acuity(BCVA), intraocular pressure(IOP, measured by Non-contact tonometer), fundus photography, fundus fluorescein angiography(FFA), indocyanine green angiography(ICG), optical coherence tomography(OCT)examination and the complications incidence were compared.<p<RESULTS:Three months after conbercept injection, the BCVA improved in 15 eyes(83%), stable in 3 eyes(17%). Before treatment, the average central macular thickness was 421.72±54.43μm, at 1 and 2 and 3mo after treatment, the average central macular thickness was 337.89±25.88μm, 293.56±26.87μm, 266.89±19.10μm respectively. There were significant differences compared with before and after injection(<i<P</i<<0.05). In the final follow up, FFA and ICG showed that the leakage in macular area disappeared in 15 eyes(83%), still existed in 3 eyes(17%), in those 3 eyes the injection was given for one or two times till the leakage disappeared. Elevated intraocular pressure occurred in 2 cases(26mmHg, 23mmHg), after 1d down to normal. Another patient showed postoperative envy, given left ofloxacin eye drops after 2d,then back to normal. There was no serious ocular adverse reactions. <p<CONCLUSION:Intravitreal injection conbercept for wAMD can significantly improve the visual function, reduce the macular edema and the leakage with higher safety and less complications. However the prolonged efficacy needs further observation. conbercept wet age related macular degeneration choroidal neovascularization Ophthalmology Shao-Feng Hao verfasserin aut In Guoji Yanke Zazhi Press of International Journal of Ophthalmology (IJO PRESS), 2017 17(2017), 8, Seite 1554-1557 (DE-627)1680946854 16725123 nnns volume:17 year:2017 number:8 pages:1554-1557 https://doi.org/10.3980/j.issn.1672-5123.2017.8.40 kostenfrei https://doaj.org/article/a22d9356a8764eb6b70a29c8c846b898 kostenfrei http://ies.ijo.cn/cn_publish/2017/8/201708040.pdf kostenfrei https://doaj.org/toc/1672-5123 Journal toc kostenfrei https://doaj.org/toc/1672-5123 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_2817 AR 17 2017 8 1554-1557 |
| allfields_unstemmed |
10.3980/j.issn.1672-5123.2017.8.40 doi (DE-627)DOAJ023830581 (DE-599)DOAJa22d9356a8764eb6b70a29c8c846b898 DE-627 ger DE-627 rakwb eng RE1-994 Ying Qin verfasserin aut Preliminary study of Conbercept injected intravitreally for the treatment of wet age-related macular degeneration 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier AIM:To observe the preliminary efficacy of conbercept injected intravitreally for the treatment of wet age-related macular degeneration(wAMD).<p<METHODS:Seventeen wAMD patients(18 eyes)were selected to receive conbercept injection. All patients were given a single conbercept injection every month, 3 times. Before and after 1, 2, 3mo of the injection, the best corrected visual acuity(BCVA), intraocular pressure(IOP, measured by Non-contact tonometer), fundus photography, fundus fluorescein angiography(FFA), indocyanine green angiography(ICG), optical coherence tomography(OCT)examination and the complications incidence were compared.<p<RESULTS:Three months after conbercept injection, the BCVA improved in 15 eyes(83%), stable in 3 eyes(17%). Before treatment, the average central macular thickness was 421.72±54.43μm, at 1 and 2 and 3mo after treatment, the average central macular thickness was 337.89±25.88μm, 293.56±26.87μm, 266.89±19.10μm respectively. There were significant differences compared with before and after injection(<i<P</i<<0.05). In the final follow up, FFA and ICG showed that the leakage in macular area disappeared in 15 eyes(83%), still existed in 3 eyes(17%), in those 3 eyes the injection was given for one or two times till the leakage disappeared. Elevated intraocular pressure occurred in 2 cases(26mmHg, 23mmHg), after 1d down to normal. Another patient showed postoperative envy, given left ofloxacin eye drops after 2d,then back to normal. There was no serious ocular adverse reactions. <p<CONCLUSION:Intravitreal injection conbercept for wAMD can significantly improve the visual function, reduce the macular edema and the leakage with higher safety and less complications. However the prolonged efficacy needs further observation. conbercept wet age related macular degeneration choroidal neovascularization Ophthalmology Shao-Feng Hao verfasserin aut In Guoji Yanke Zazhi Press of International Journal of Ophthalmology (IJO PRESS), 2017 17(2017), 8, Seite 1554-1557 (DE-627)1680946854 16725123 nnns volume:17 year:2017 number:8 pages:1554-1557 https://doi.org/10.3980/j.issn.1672-5123.2017.8.40 kostenfrei https://doaj.org/article/a22d9356a8764eb6b70a29c8c846b898 kostenfrei http://ies.ijo.cn/cn_publish/2017/8/201708040.pdf kostenfrei https://doaj.org/toc/1672-5123 Journal toc kostenfrei https://doaj.org/toc/1672-5123 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_2817 AR 17 2017 8 1554-1557 |
| allfieldsGer |
10.3980/j.issn.1672-5123.2017.8.40 doi (DE-627)DOAJ023830581 (DE-599)DOAJa22d9356a8764eb6b70a29c8c846b898 DE-627 ger DE-627 rakwb eng RE1-994 Ying Qin verfasserin aut Preliminary study of Conbercept injected intravitreally for the treatment of wet age-related macular degeneration 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier AIM:To observe the preliminary efficacy of conbercept injected intravitreally for the treatment of wet age-related macular degeneration(wAMD).<p<METHODS:Seventeen wAMD patients(18 eyes)were selected to receive conbercept injection. All patients were given a single conbercept injection every month, 3 times. Before and after 1, 2, 3mo of the injection, the best corrected visual acuity(BCVA), intraocular pressure(IOP, measured by Non-contact tonometer), fundus photography, fundus fluorescein angiography(FFA), indocyanine green angiography(ICG), optical coherence tomography(OCT)examination and the complications incidence were compared.<p<RESULTS:Three months after conbercept injection, the BCVA improved in 15 eyes(83%), stable in 3 eyes(17%). Before treatment, the average central macular thickness was 421.72±54.43μm, at 1 and 2 and 3mo after treatment, the average central macular thickness was 337.89±25.88μm, 293.56±26.87μm, 266.89±19.10μm respectively. There were significant differences compared with before and after injection(<i<P</i<<0.05). In the final follow up, FFA and ICG showed that the leakage in macular area disappeared in 15 eyes(83%), still existed in 3 eyes(17%), in those 3 eyes the injection was given for one or two times till the leakage disappeared. Elevated intraocular pressure occurred in 2 cases(26mmHg, 23mmHg), after 1d down to normal. Another patient showed postoperative envy, given left ofloxacin eye drops after 2d,then back to normal. There was no serious ocular adverse reactions. <p<CONCLUSION:Intravitreal injection conbercept for wAMD can significantly improve the visual function, reduce the macular edema and the leakage with higher safety and less complications. However the prolonged efficacy needs further observation. conbercept wet age related macular degeneration choroidal neovascularization Ophthalmology Shao-Feng Hao verfasserin aut In Guoji Yanke Zazhi Press of International Journal of Ophthalmology (IJO PRESS), 2017 17(2017), 8, Seite 1554-1557 (DE-627)1680946854 16725123 nnns volume:17 year:2017 number:8 pages:1554-1557 https://doi.org/10.3980/j.issn.1672-5123.2017.8.40 kostenfrei https://doaj.org/article/a22d9356a8764eb6b70a29c8c846b898 kostenfrei http://ies.ijo.cn/cn_publish/2017/8/201708040.pdf kostenfrei https://doaj.org/toc/1672-5123 Journal toc kostenfrei https://doaj.org/toc/1672-5123 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_2817 AR 17 2017 8 1554-1557 |
| allfieldsSound |
10.3980/j.issn.1672-5123.2017.8.40 doi (DE-627)DOAJ023830581 (DE-599)DOAJa22d9356a8764eb6b70a29c8c846b898 DE-627 ger DE-627 rakwb eng RE1-994 Ying Qin verfasserin aut Preliminary study of Conbercept injected intravitreally for the treatment of wet age-related macular degeneration 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier AIM:To observe the preliminary efficacy of conbercept injected intravitreally for the treatment of wet age-related macular degeneration(wAMD).<p<METHODS:Seventeen wAMD patients(18 eyes)were selected to receive conbercept injection. All patients were given a single conbercept injection every month, 3 times. Before and after 1, 2, 3mo of the injection, the best corrected visual acuity(BCVA), intraocular pressure(IOP, measured by Non-contact tonometer), fundus photography, fundus fluorescein angiography(FFA), indocyanine green angiography(ICG), optical coherence tomography(OCT)examination and the complications incidence were compared.<p<RESULTS:Three months after conbercept injection, the BCVA improved in 15 eyes(83%), stable in 3 eyes(17%). Before treatment, the average central macular thickness was 421.72±54.43μm, at 1 and 2 and 3mo after treatment, the average central macular thickness was 337.89±25.88μm, 293.56±26.87μm, 266.89±19.10μm respectively. There were significant differences compared with before and after injection(<i<P</i<<0.05). In the final follow up, FFA and ICG showed that the leakage in macular area disappeared in 15 eyes(83%), still existed in 3 eyes(17%), in those 3 eyes the injection was given for one or two times till the leakage disappeared. Elevated intraocular pressure occurred in 2 cases(26mmHg, 23mmHg), after 1d down to normal. Another patient showed postoperative envy, given left ofloxacin eye drops after 2d,then back to normal. There was no serious ocular adverse reactions. <p<CONCLUSION:Intravitreal injection conbercept for wAMD can significantly improve the visual function, reduce the macular edema and the leakage with higher safety and less complications. However the prolonged efficacy needs further observation. conbercept wet age related macular degeneration choroidal neovascularization Ophthalmology Shao-Feng Hao verfasserin aut In Guoji Yanke Zazhi Press of International Journal of Ophthalmology (IJO PRESS), 2017 17(2017), 8, Seite 1554-1557 (DE-627)1680946854 16725123 nnns volume:17 year:2017 number:8 pages:1554-1557 https://doi.org/10.3980/j.issn.1672-5123.2017.8.40 kostenfrei https://doaj.org/article/a22d9356a8764eb6b70a29c8c846b898 kostenfrei http://ies.ijo.cn/cn_publish/2017/8/201708040.pdf kostenfrei https://doaj.org/toc/1672-5123 Journal toc kostenfrei https://doaj.org/toc/1672-5123 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_2817 AR 17 2017 8 1554-1557 |
| language |
English |
| source |
In Guoji Yanke Zazhi 17(2017), 8, Seite 1554-1557 volume:17 year:2017 number:8 pages:1554-1557 |
| sourceStr |
In Guoji Yanke Zazhi 17(2017), 8, Seite 1554-1557 volume:17 year:2017 number:8 pages:1554-1557 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
conbercept wet age related macular degeneration choroidal neovascularization Ophthalmology |
| isfreeaccess_bool |
true |
| container_title |
Guoji Yanke Zazhi |
| authorswithroles_txt_mv |
Ying Qin @@aut@@ Shao-Feng Hao @@aut@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
1680946854 |
| id |
DOAJ023830581 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ023830581</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307070921.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3980/j.issn.1672-5123.2017.8.40</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ023830581</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJa22d9356a8764eb6b70a29c8c846b898</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RE1-994</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ying Qin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Preliminary study of Conbercept injected intravitreally for the treatment of wet age-related macular degeneration</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">AIM:To observe the preliminary efficacy of conbercept injected intravitreally for the treatment of wet age-related macular degeneration(wAMD).<p<METHODS:Seventeen wAMD patients(18 eyes)were selected to receive conbercept injection. All patients were given a single conbercept injection every month, 3 times. Before and after 1, 2, 3mo of the injection, the best corrected visual acuity(BCVA), intraocular pressure(IOP, measured by Non-contact tonometer), fundus photography, fundus fluorescein angiography(FFA), indocyanine green angiography(ICG), optical coherence tomography(OCT)examination and the complications incidence were compared.<p<RESULTS:Three months after conbercept injection, the BCVA improved in 15 eyes(83%), stable in 3 eyes(17%). Before treatment, the average central macular thickness was 421.72±54.43μm, at 1 and 2 and 3mo after treatment, the average central macular thickness was 337.89±25.88μm, 293.56±26.87μm, 266.89±19.10μm respectively. There were significant differences compared with before and after injection(<i<P</i<<0.05). In the final follow up, FFA and ICG showed that the leakage in macular area disappeared in 15 eyes(83%), still existed in 3 eyes(17%), in those 3 eyes the injection was given for one or two times till the leakage disappeared. Elevated intraocular pressure occurred in 2 cases(26mmHg, 23mmHg), after 1d down to normal. Another patient showed postoperative envy, given left ofloxacin eye drops after 2d,then back to normal. There was no serious ocular adverse reactions. <p<CONCLUSION:Intravitreal injection conbercept for wAMD can significantly improve the visual function, reduce the macular edema and the leakage with higher safety and less complications. However the prolonged efficacy needs further observation.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">conbercept</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">wet age related macular degeneration</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">choroidal neovascularization</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Ophthalmology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shao-Feng Hao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Guoji Yanke Zazhi</subfield><subfield code="d">Press of International Journal of Ophthalmology (IJO PRESS), 2017</subfield><subfield code="g">17(2017), 8, Seite 1554-1557</subfield><subfield code="w">(DE-627)1680946854</subfield><subfield code="x">16725123</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:8</subfield><subfield code="g">pages:1554-1557</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3980/j.issn.1672-5123.2017.8.40</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/a22d9356a8764eb6b70a29c8c846b898</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://ies.ijo.cn/cn_publish/2017/8/201708040.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1672-5123</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1672-5123</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2817</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">2017</subfield><subfield code="e">8</subfield><subfield code="h">1554-1557</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Ying Qin |
| spellingShingle |
Ying Qin misc RE1-994 misc conbercept misc wet age related macular degeneration misc choroidal neovascularization misc Ophthalmology Preliminary study of Conbercept injected intravitreally for the treatment of wet age-related macular degeneration |
| authorStr |
Ying Qin |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1680946854 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RE1-994 |
| illustrated |
Not Illustrated |
| issn |
16725123 |
| topic_title |
RE1-994 Preliminary study of Conbercept injected intravitreally for the treatment of wet age-related macular degeneration conbercept wet age related macular degeneration choroidal neovascularization |
| topic |
misc RE1-994 misc conbercept misc wet age related macular degeneration misc choroidal neovascularization misc Ophthalmology |
| topic_unstemmed |
misc RE1-994 misc conbercept misc wet age related macular degeneration misc choroidal neovascularization misc Ophthalmology |
| topic_browse |
misc RE1-994 misc conbercept misc wet age related macular degeneration misc choroidal neovascularization misc Ophthalmology |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Guoji Yanke Zazhi |
| hierarchy_parent_id |
1680946854 |
| hierarchy_top_title |
Guoji Yanke Zazhi |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1680946854 |
| title |
Preliminary study of Conbercept injected intravitreally for the treatment of wet age-related macular degeneration |
| ctrlnum |
(DE-627)DOAJ023830581 (DE-599)DOAJa22d9356a8764eb6b70a29c8c846b898 |
| title_full |
Preliminary study of Conbercept injected intravitreally for the treatment of wet age-related macular degeneration |
| author_sort |
Ying Qin |
| journal |
Guoji Yanke Zazhi |
| journalStr |
Guoji Yanke Zazhi |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
txt |
| container_start_page |
1554 |
| author_browse |
Ying Qin Shao-Feng Hao |
| container_volume |
17 |
| class |
RE1-994 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Ying Qin |
| doi_str_mv |
10.3980/j.issn.1672-5123.2017.8.40 |
| author2-role |
verfasserin |
| title_sort |
preliminary study of conbercept injected intravitreally for the treatment of wet age-related macular degeneration |
| callnumber |
RE1-994 |
| title_auth |
Preliminary study of Conbercept injected intravitreally for the treatment of wet age-related macular degeneration |
| abstract |
AIM:To observe the preliminary efficacy of conbercept injected intravitreally for the treatment of wet age-related macular degeneration(wAMD).<p<METHODS:Seventeen wAMD patients(18 eyes)were selected to receive conbercept injection. All patients were given a single conbercept injection every month, 3 times. Before and after 1, 2, 3mo of the injection, the best corrected visual acuity(BCVA), intraocular pressure(IOP, measured by Non-contact tonometer), fundus photography, fundus fluorescein angiography(FFA), indocyanine green angiography(ICG), optical coherence tomography(OCT)examination and the complications incidence were compared.<p<RESULTS:Three months after conbercept injection, the BCVA improved in 15 eyes(83%), stable in 3 eyes(17%). Before treatment, the average central macular thickness was 421.72±54.43μm, at 1 and 2 and 3mo after treatment, the average central macular thickness was 337.89±25.88μm, 293.56±26.87μm, 266.89±19.10μm respectively. There were significant differences compared with before and after injection(<i<P</i<<0.05). In the final follow up, FFA and ICG showed that the leakage in macular area disappeared in 15 eyes(83%), still existed in 3 eyes(17%), in those 3 eyes the injection was given for one or two times till the leakage disappeared. Elevated intraocular pressure occurred in 2 cases(26mmHg, 23mmHg), after 1d down to normal. Another patient showed postoperative envy, given left ofloxacin eye drops after 2d,then back to normal. There was no serious ocular adverse reactions. <p<CONCLUSION:Intravitreal injection conbercept for wAMD can significantly improve the visual function, reduce the macular edema and the leakage with higher safety and less complications. However the prolonged efficacy needs further observation. |
| abstractGer |
AIM:To observe the preliminary efficacy of conbercept injected intravitreally for the treatment of wet age-related macular degeneration(wAMD).<p<METHODS:Seventeen wAMD patients(18 eyes)were selected to receive conbercept injection. All patients were given a single conbercept injection every month, 3 times. Before and after 1, 2, 3mo of the injection, the best corrected visual acuity(BCVA), intraocular pressure(IOP, measured by Non-contact tonometer), fundus photography, fundus fluorescein angiography(FFA), indocyanine green angiography(ICG), optical coherence tomography(OCT)examination and the complications incidence were compared.<p<RESULTS:Three months after conbercept injection, the BCVA improved in 15 eyes(83%), stable in 3 eyes(17%). Before treatment, the average central macular thickness was 421.72±54.43μm, at 1 and 2 and 3mo after treatment, the average central macular thickness was 337.89±25.88μm, 293.56±26.87μm, 266.89±19.10μm respectively. There were significant differences compared with before and after injection(<i<P</i<<0.05). In the final follow up, FFA and ICG showed that the leakage in macular area disappeared in 15 eyes(83%), still existed in 3 eyes(17%), in those 3 eyes the injection was given for one or two times till the leakage disappeared. Elevated intraocular pressure occurred in 2 cases(26mmHg, 23mmHg), after 1d down to normal. Another patient showed postoperative envy, given left ofloxacin eye drops after 2d,then back to normal. There was no serious ocular adverse reactions. <p<CONCLUSION:Intravitreal injection conbercept for wAMD can significantly improve the visual function, reduce the macular edema and the leakage with higher safety and less complications. However the prolonged efficacy needs further observation. |
| abstract_unstemmed |
AIM:To observe the preliminary efficacy of conbercept injected intravitreally for the treatment of wet age-related macular degeneration(wAMD).<p<METHODS:Seventeen wAMD patients(18 eyes)were selected to receive conbercept injection. All patients were given a single conbercept injection every month, 3 times. Before and after 1, 2, 3mo of the injection, the best corrected visual acuity(BCVA), intraocular pressure(IOP, measured by Non-contact tonometer), fundus photography, fundus fluorescein angiography(FFA), indocyanine green angiography(ICG), optical coherence tomography(OCT)examination and the complications incidence were compared.<p<RESULTS:Three months after conbercept injection, the BCVA improved in 15 eyes(83%), stable in 3 eyes(17%). Before treatment, the average central macular thickness was 421.72±54.43μm, at 1 and 2 and 3mo after treatment, the average central macular thickness was 337.89±25.88μm, 293.56±26.87μm, 266.89±19.10μm respectively. There were significant differences compared with before and after injection(<i<P</i<<0.05). In the final follow up, FFA and ICG showed that the leakage in macular area disappeared in 15 eyes(83%), still existed in 3 eyes(17%), in those 3 eyes the injection was given for one or two times till the leakage disappeared. Elevated intraocular pressure occurred in 2 cases(26mmHg, 23mmHg), after 1d down to normal. Another patient showed postoperative envy, given left ofloxacin eye drops after 2d,then back to normal. There was no serious ocular adverse reactions. <p<CONCLUSION:Intravitreal injection conbercept for wAMD can significantly improve the visual function, reduce the macular edema and the leakage with higher safety and less complications. However the prolonged efficacy needs further observation. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_2817 |
| container_issue |
8 |
| title_short |
Preliminary study of Conbercept injected intravitreally for the treatment of wet age-related macular degeneration |
| url |
https://doi.org/10.3980/j.issn.1672-5123.2017.8.40 https://doaj.org/article/a22d9356a8764eb6b70a29c8c846b898 http://ies.ijo.cn/cn_publish/2017/8/201708040.pdf https://doaj.org/toc/1672-5123 |
| remote_bool |
true |
| author2 |
Shao-Feng Hao |
| author2Str |
Shao-Feng Hao |
| ppnlink |
1680946854 |
| callnumber-subject |
RE - Ophthalmology |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.3980/j.issn.1672-5123.2017.8.40 |
| callnumber-a |
RE1-994 |
| up_date |
2024-07-03T19:42:56.006Z |
| _version_ |
1803588233867558912 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ023830581</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307070921.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3980/j.issn.1672-5123.2017.8.40</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ023830581</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJa22d9356a8764eb6b70a29c8c846b898</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RE1-994</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ying Qin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Preliminary study of Conbercept injected intravitreally for the treatment of wet age-related macular degeneration</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">AIM:To observe the preliminary efficacy of conbercept injected intravitreally for the treatment of wet age-related macular degeneration(wAMD).<p<METHODS:Seventeen wAMD patients(18 eyes)were selected to receive conbercept injection. All patients were given a single conbercept injection every month, 3 times. Before and after 1, 2, 3mo of the injection, the best corrected visual acuity(BCVA), intraocular pressure(IOP, measured by Non-contact tonometer), fundus photography, fundus fluorescein angiography(FFA), indocyanine green angiography(ICG), optical coherence tomography(OCT)examination and the complications incidence were compared.<p<RESULTS:Three months after conbercept injection, the BCVA improved in 15 eyes(83%), stable in 3 eyes(17%). Before treatment, the average central macular thickness was 421.72±54.43μm, at 1 and 2 and 3mo after treatment, the average central macular thickness was 337.89±25.88μm, 293.56±26.87μm, 266.89±19.10μm respectively. There were significant differences compared with before and after injection(<i<P</i<<0.05). In the final follow up, FFA and ICG showed that the leakage in macular area disappeared in 15 eyes(83%), still existed in 3 eyes(17%), in those 3 eyes the injection was given for one or two times till the leakage disappeared. Elevated intraocular pressure occurred in 2 cases(26mmHg, 23mmHg), after 1d down to normal. Another patient showed postoperative envy, given left ofloxacin eye drops after 2d,then back to normal. There was no serious ocular adverse reactions. <p<CONCLUSION:Intravitreal injection conbercept for wAMD can significantly improve the visual function, reduce the macular edema and the leakage with higher safety and less complications. However the prolonged efficacy needs further observation.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">conbercept</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">wet age related macular degeneration</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">choroidal neovascularization</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Ophthalmology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shao-Feng Hao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Guoji Yanke Zazhi</subfield><subfield code="d">Press of International Journal of Ophthalmology (IJO PRESS), 2017</subfield><subfield code="g">17(2017), 8, Seite 1554-1557</subfield><subfield code="w">(DE-627)1680946854</subfield><subfield code="x">16725123</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:8</subfield><subfield code="g">pages:1554-1557</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3980/j.issn.1672-5123.2017.8.40</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/a22d9356a8764eb6b70a29c8c846b898</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://ies.ijo.cn/cn_publish/2017/8/201708040.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1672-5123</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1672-5123</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2817</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">2017</subfield><subfield code="e">8</subfield><subfield code="h">1554-1557</subfield></datafield></record></collection>
|
| score |
7.4010077 |